Completed Clinical Trials:

• A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201, free of complexing proteins, in the treatment of glabellar frown lines.
  
  
• A split face, double-blind, randomized clinical trial of the effects of RV3718A using two applications per day to the half face for 3 months followed by 2 applications per day to the whole face for 3 months.


• The P.U.M.P Study: Patients using MICRO properly; an open-label, community based, phase IV study to assess facial acne improvement with the use of Retin-A Micro (Tretinoin gel) microsphere, 0.04% or 0.1% in a pump dispenser.


• A Phase III, randomized, placebo-controlled, multi-center, double-blind study of the safety and duration of efficacy of Reloxin (Botulinum Type A Toxin) in correction of moderate to severe glabellar lines (and including a sub-study to detect any treatment-related QT interval changes).


• A multi-center, Phase 3, randomized, double-blind, clinical trial to compare the safety and efficacy Clin-RA Gel vs. Clindamycin Phosphate 1.2% Gel in the treatment of acne vulgaris.


• Protocol C-05-16 Treatment of the upper arms using the ThermaCool System.


• To demonstrate the ability of Onion extract cream (Mederma Cream plus SPF) to improve the cosmetic appearance of post laser scar removal.

Ongoing Clinical Trials:

• Open-label, randomized, split-face study to evaluate the efficacy, safety and subject satisfaction of pain management during and after Restylane dermal filler injections for the correction of nasolabial folds.


• A phase ¾ multi-center, open-label extension study to assess the long-term safety of repeat administrations of Reloxin in the treatment of glabellar lines


• A prospective, randomized, double-blind, placebo controlled, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines.

back to top